A prospective observational study on adverse drug reactions of iohexol contrast media in computed tomography imaging studies


  • Prashant P. Shivgunde University Research Department, Maharashtra University of Health Sciences (MUHS), Mhasrul, Vani-Dindori Road, Nashik, Maharashtra, India
  • Ganesh Ashok Chepuri University Research Department, Maharashtra University of Health Sciences (MUHS), Mhasrul, Vani-Dindori Road, Nashik, Maharashtra, India




Adverse drug reaction, Computed tomography, Contrast media, Iohexol, Radiology


Background: Iohexol is widely used radiocontrast media in the radiology departments for the diagnostic imaging purpose. As very few studies are carried out focusing on safety profiles of this contrast media. This study was conducted to know the profile of adverse drug reactions (ADRs) induced by Iohexol in patients who are undergoing the contrast-enhanced computed tomography (CECT) examination.

Methods: Total 106 patients from CT unit of radiology department were observed for adverse drug reactions from Iohexol contrast media in 2 months duration. Acute ADRs were recorded immediately after contrast media administration by observation and personal interviews and delayed ADRs are recorded by follow up after 24hrs.

Results: Total 23 out of 106 patients who had undergone CT imaging investigations by Iohexol contrast media had developed ADRs. Total 29 ADRs were developed in 23 patients. Out of these, 22 ADRs were acute and 7 ADRs were delayed reactions. All acute ADRs were of “probable” category and all delayed ADRs were of “possible” category according to WHO-UMC and Naranjo’s causality assessment scales. All ADRs were at Level-1 according to Modified Hartwig and Siegel severity scale. Preventability assessment of ADRs using Modified Schumock and Thornton preventability scale showed that all the ADRs were of “not preventable” class. All 29 ADRs were of TYPE U (Unclassified) as per the Wills and Brown method.

Conclusions: All reactions are physiologic and are mild in nature. No life-threatening reactions are observed during the entire study period. Development of ADRs in female patients seen higher than male patients. So, this population requires a special attention for any serious contrast media reactions.


Beckett KR, Moriarity AK, Langer JM. Safe use of contrast media: what the radiologist needs to know. Radio Graphics. 2015;35(6):1738-50.

OECD Statistics. Health, Health care utilization: Diagnostic exams. Available at: https://stats.oecd.org/

Contrast Enhancement Agents. In: Whitley AS, Alsop CW, Moore AD, Eds. Clark's Special Procedures in Diagnostic Imaging, 1st ed. Oxford: Butterworth-Heinemann; 1999: 41-62.

ACR manual on contrast media: version 10.3. ACR Committee on Drugs and Contrast Media. American College of Radiology. Published 2017. Available at: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf

Böhm I, Alfke H, Klose KJ. Hypersensitivity reactions and contrast medium injection: are they always related?. Eur J Radiol. 2011;80(2):368-72.

Böhm I. Latex allergy in patients suspected for contrast media hypersensitivity: A neglected differential diagnosis. Acta Radiol. 2010;51(6):709-10.

Dewachter P, Laroche D, Mouton-Faivre C, Bloch-Morot E, Cercueil JP, Metge L, et al. Immediate reactions following iodinated contrast media injection: a study of 38 cases. Eur J Radiol. 2011;77(3):495-501.

Iyer RS, Schopp JG, Swanson JO, Thapa MM, Phillips GS. Safety Essentials: Acute reactions to iodinated contrast media. Can Assoc Radiol J. 2013;64(3):193-9.

WHO. The use of the WHO-UMC system for standardised case causality assessment, Sweden. The Uppsala Monitoring Centre. Available at: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229-32.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Am J Hosp Pharm. 1992;27(6):538.

Wills S, Brown DA. A proposed new means of classifying adverse drug reactions to medicines. Pharm J. 1999;262(7030):163-5.

Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. a report from the Japanese committee on the safety of contrast media. Radiology. 1990;175(3):621-8.

Namasivayam S, Kalra MK, Torres WE, Small WC. Adverse reactions to intravenous iodinated contrast media: an update. Curr Probl Diagn Radiol. 2006;35(4):164-9.

Thomsen HS, Morcos SK. Contrast media safety committee of european society of urogenital radiology. Management of acute adverse reactions to contrast media. Eur Radiol. 2004;14(3):476-81.

Webb JA, Stacul F, Thomsen HS, Morcos SK. Members of the contrast media safety committee of the european society of urogenital radiology. late adverse reactions to intravascular iodinated contrast media. Eur Radiol. 2003;13(1):181-4.

Celik I, Hoppe M, Lorenz W, Sitter H, Ishaque N, Jungraithmayr W, et al. Randomised study comparing a non-ionic with an ionic contrast medium in patients with malignancies: First answer with a new diagnostic approach. Inflamm Res. 1999;48(1):47-8.

Rathaur V, Dutt HK, Rawat V, Joshi P. Three cases of iohexol induced seizures in paediatric patients undergoing CECT head and the role of pharmacovigilance. J App Pharm Sci. 2014;4(8):075-6.




How to Cite

Shivgunde, P. P., & Chepuri, G. A. (2019). A prospective observational study on adverse drug reactions of iohexol contrast media in computed tomography imaging studies. International Journal of Basic & Clinical Pharmacology, 8(7), 1667–1672. https://doi.org/10.18203/2319-2003.ijbcp20192669



Original Research Articles